Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Rémi Delva
Observed names:
R Delva,
R. Delva
Institution:
Institut de Cancérologie de l'Ouest
Observed institutions:
Institut Gustave Roussy,
Centre Hospitalier Universitaire de Bordeaux,
Institut de Cancérologie de l'Ouest,
Centre Eugène Marquis,
Centre Hospitalier Universitaire de Limoges,
Institut Claudius Regaud,
Centre Oscar Lambret,
Université d'Angers
show all 8
OpenAlex ID:
A5108211854
Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP)
2007
·
S. Culine
, P. Kerbrat
, et al.
·
Annals of Oncology
·
218
Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy
2010
·
F.-C. Bidard
, C. Mathiot
, et al.
·
Annals of Oncology
·
160
6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial
2019
·
Xavier Pivot
, Gilles Romieu
, et al.
·
The Lancet
·
143
PDF
High prognostic significance of residual disease after neoadjuvant chemotherapy: a retrospective study in 710 patients with operable breast cancer
2005
·
Sophie Catherine Abrial
, Frédérique Penault-Llorca
, et al.
·
Breast Cancer Research and Treatment
·
116
Do cytokines improve survival in patients with metastatic renal cell carcinoma (MRCC) of intermediate prognosis? Results of the prospective randomized PERCY Quattro trial
2005
·
S. Negrier
, D. Perol
, et al.
·
Journal of Clinical Oncology
·
89
Prospective analysis of the impact of VEGF‐A gene polymorphisms on the pharmacodynamics of bevacizumab‐based therapy in metastatic breast cancer patients
2010
·
Marie‐Christine Etienne‐Grimaldi
, Patricia Formento
, et al.
·
British Journal of Clinical Pharmacology
·
75
PDF
A Risk-adapted Study of Cisplatin and Etoposide, with or Without Ifosfamide, in Patients with Metastatic Seminoma: Results of the GETUG S99 Multicenter Prospective Study
2013
·
Karim Fizazi
, Rémi Delva
, et al.
·
European Urology
·
53
First-line bevacizumab-containing therapy for breast cancer: results in patients aged ≥70 years treated in the ATHENA study
2011
·
L. Biganzoli
, E. Di Vincenzo
, et al.
·
Annals of Oncology
·
53
PDF
Neuroendocrine Carcinoma of the Urinary Bladder: A Large, Retrospective Study From the French Genito-Urinary Tumor Group
2019
·
Marine Sroussi
, Reza Elaidi
, et al.
·
Clinical Genitourinary Cancer
·
27
A Randomized, Open-label, Cross-over Phase 2 Trial of Darolutamide and Enzalutamide in Men with Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer: Patient Preference and Cognitive Function in ODENZA
2023
·
Emeline Colomba
, Sarah Flora Jonas
, et al.
·
European Urology
·
22
Use of liposomal doxorubicin–cyclophosphamide combination in breast cancer patients with brain metastases: a monocentric retrospective study
2014
·
B. Linot
, M. Campone
, et al.
·
Journal of Neuro-Oncology
·
22
Pathological and Clinical Response of a Primary Chemotherapy Regimen Combining Vinorelbine, Epirubicin, and Paclitaxel as Neoadjuvant Treatment in Patients with Operable Breast Cancer
2005
·
Catherine Abrial
, Isabelle Van Praagh
, et al.
·
The Oncologist
·
12
Tumor Parameters, Clinical and Pathological Responses, Medical Management, and Survival Through Time on 710 Operable Breast Cancers
2005
·
C. Abrial
, M. A. Mouret-Reynier
, et al.
·
Medical Oncology
·
12
High Prognostic Significance of Residual Disease After Neoadjuvant Chemotherapy: a Retrospective Study in 710 Patients with Operable Breast Cancer
2006
·
Sophie Catherine Abrial
, Frédérique Penault-Llorca
, et al.
·
Breast Cancer Research and Treatment
·
11
PDF
High rate of extra-haematological toxicity compromises dose-dense sequential adjuvant chemotherapy for breast cancer
2011
·
E Brain
, C Levy
, et al.
·
British Journal of Cancer
·
7
PDF
Rapidly recycled, intensive alternating chemotherapy in heavily pretreated progressive nonseminomatous germ cell tumors a feasibility study
1995
·
S. Culine
, J.P. Droz
, et al.
·
Urologic Oncology Seminars and Original Investigations
·
5
Sequential Addition of an Anthracycline-Based Regimen to Docetaxel as Neoadjuvant Chemotherapy in Patients with Operable Breast Cancer
2006
·
Sophie Amat
, Marie-Ange Mouret-Reynier
, et al.
·
Clinical Breast Cancer
·
3
rIL-2 in metastatic soft tissue sarcomas refractory to chemotherapy: response and enhancement of further chemosensitivity.
1998
·
G Gravis
, P Viens
, et al.
·
PubMed
·
3
[Ambulatory blood pressure in normotensive subjects. Definition of reference values as a function of age by the Spacelabs instrument].
1987
·
J Y Pagny
, R Delva
, et al.
·
PubMed
·
3
The value of early decrease in CA125 levels as a prognostic or surrogate marker for disease progression in patients with recurrent ovarian cancer: Results from the CALYPSO study.
2010
·
R. J. Simes
, C. K. Lee
, et al.
·
Journal of Clinical Oncology
·
2
A risk-adapted study of cisplatin and etoposide, with or without ifosfamide, in patients with metastatic seminoma: Results of the GETUG S99 multicenter prospective study
2009
·
K. Fizazi
, M. Aubelle
, et al.
·
Journal of Clinical Oncology
·
2
713P Assessment of bleomycin pulmonary toxicity in men with poor-prognosis non-seminomatous germ-cell tumors treated in the GETUG 13 phase III trial
2021
·
N. Naoun
, G. Le Teuff
, et al.
·
Annals of Oncology
·
1
Neuroendocrine carcinoma of the urinary bladder: A large analysis of the French GETUG consortium
2018
·
M. Sroussi
, M. Lorcet
, et al.
·
Annals of Oncology
·
1
Assessing 2-month clinical prognosis in patients with solid tumors: First results of PRONOPALL study.
2011
·
H. P. Bourgeois
, S. Traoré
, et al.
·
Journal of Clinical Oncology
·
1
Étude de phase IV de pharmacovigilance portant sur la toxicité cardiaque du trastuzumab en néoadjuvant et adjuvant dans le cancer du sein. Analyse conduite par l’Observatoire des Médicaments et des Innovations Thérapeutiques de Bretagne et des Pays de la Loire (OMIT B PL)
2010
·
F. Grudé
, M. Campone
, et al.
·
ONCOLOGIE
·
1
Show more works
View as search
Works count:
33
Citation count:
1,043
H-index:
12
I10-index:
14
Year
Topic
Type